Rutgers, The State University of New Jersey
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rutgers, The State University of New Jersey sits in the top decile of US sponsors by registered trial count (#86 of 15,742 sponsors by registered trial count).
Rutgers, The State University of New Jersey: 413 sponsored US clinical trials, 109 recruiting.
Rutgers, The State University of New Jersey sponsors 413 registered US clinical trials on ClinicalTrials.gov, 109 of them currently recruiting, and 196 completed. 35 of these trials are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 6 trials.
Top-decile sponsor footprint
Rutgers, The State University of New Jersey ranks in the top decile of sponsors by registered trial count (#86 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 267 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
413 total, page 5 of 9
Rutgers Pilot for PREDICT- Patient POC Test
NCT05612724
E-Manage: A Brief mHelath Intervention for University Students
NCT04636151
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
NCT04605588
Breast Cancer and Resistance Exercise Program
NCT04562233
Literacy Promotion for Latinos Study
NCT04609553
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
NCT04146038
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
NCT03272633
Aggrenox To Treat Acute Covid-19
NCT04410328
Safety and Feasibility of the Infinity Catheter for Radial Access
NCT04553549
Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students
NCT04558411
Music to Reduce Patient Reported Pain During Intrauterine Device (IUD) Placement in the Office
NCT05068245
Mindfulness Oriented Recovery Enhancement for Chronic Pain and Opioid Relapse
NCT04491968
ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19
NCT04460677
Opioid Analgesic Reduction Study (OARS) - Pilot
NCT05283499
Bilingual Family Literacy Program Pilot
NCT04423133
Ibuprofen Inhibits Human Sweet Taste
NCT06291337
COVID-19 Wellness Survey
NCT04394104
Rutgers COVID-19 Cohort Study
NCT04336215
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
NCT04336332
Yoga for Anxiety in Adults
NCT04240899
Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin
NCT04163952
mHealth Mindfulness for Dementia Caregivers
NCT04150055
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
NCT03636373
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
NCT04081688
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
NCT03985761
Feasibility of a Self-Management + Peer Mentoring Intervention for Adolescent and Young Adult Childhood Cancer Survivors
NCT04075734
Intraosseous Catheter Confirmation Study
NCT03908879
The Effect of Concord Grape Polyphenol-soy Protein Isolate Complex (GP-SPI) on Gut Microbiota
NCT04018066
A Family Literacy Program for Latino Families
NCT03941197
Couple-focused Intervention for Sun Protection
NCT04549675
Heart Rate Variability Biofeedback for Smoking Cessation
NCT03972137
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
NCT03873337
Apneic Oxygenation Including Precipitous Intubations During RSI in the ED
NCT03694379
Pharmacokinetics and Pharmacodynamics of Anthocyanins
NCT03650140
Pilot of Mindfulness Oriented Recovery Enhancement in MethadoneTreatment
NCT03894501
Dialectical Behavior Therapy for Adolescents at Rutgers University
NCT03861858
Developmental Monitoring and Language Promotion
NCT03732911
TENS and Opioid Use After Cesarean Delivery
NCT03843788
Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma
NCT03725449
Rib Raising for Post-operative Ileus
NCT03662672
Modifying Young Adult Skin Cancer Risk and Protective Behaviors
NCT03313492
Resurgence as Choice: Basic and Clinical Studies
NCT03423940
Fiber Mix and Glycemic Response
NCT03334643
Tobacco and Socioeconomic Disadvantage
NCT03620708
Assuring Patient-centered Literacy Promotion for Underserved Children Study
NCT03242850
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
NCT03112668
Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
NCT02885649
Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project
NCT03326713
Quality of Life Outcomes in Spinal Cord Stimulation
NCT03249922
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
NCT03239665
What is open in the Rutgers, The State University of New Jersey pipeline
109 recruiting of 413 indexed (26% open); 196 completed (47%).
Phase mix: 35 late (III/IV) vs 104 early (I/II) (early-phase heavy).
Top condition: Autism Spectrum Disorder (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rutgers, The State University of New Jersey: open-pipeline peers nationwide
Peers matched on 413 registered trials and 26% open enrollment, not the therapeutic-area sidebar.
Rutgers, The State University of New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 413 trials (± recruiting share)
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 26% open enrollment (± trial volume)
- Coherus Oncology · 27% recruiting · 15 trials
- NewAmsterdam Pharma · 27% recruiting · 15 trials
- Portland VA Medical Center · 27% recruiting · 15 trials
- White River Junction Veterans Affairs Medical Center · 27% recruiting · 15 trials
Related
What to do with this Rutgers, The State University of New Jersey page
413 registered trials is a research-attention snapshot, not an endorsement of Rutgers, The State University of New Jersey or any single study.
- 109 of Rutgers, The State University of New Jersey's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Autism Spectrum Disorder is the condition Rutgers, The State University of New Jersey studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autism Spectrum Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rutgers, The State University of New Jersey pipeline card: 413 registered trials from official public datasets.Report a data error.